newsFostamatinib reduces COVID-19 risks by 50 percent in Phase II study2 September 2021 | By Anna Begley (European Pharmaceutical Review)Fostamatinib significantly reduced serious adverse effects and risk of death in hospitalised COVID-19 patients, shows Phase II study.
newsInterleukin-6 inhibitors improve outcomes for COVID-19 patients in study5 August 2020 | By Victoria Rees (European Pharmaceutical Review)Researchers have shown that symptoms in patients experiencing severe COVID-19 improved when given either sarilumab or tocilizumab, interleukin-6 inhibitors.